GE HealthCare Technologies reported second-quarter fiscal 2026 revenue of $5.30 billion, beating analyst estimates of $5.27 billion and growing 5.8% year on year, while adjusted earnings per share of $1.13 surpassed the consensus of $1.04 by 9.1%. Organic revenue rose 3.5% year on year, driven by robust orders growth particularly in Pharmaceutical Diagnostics and Advanced Imaging Solutions, with total orders up 11% and backlog reaching a record $23.9 billion. Management reiterated full-year adjusted EPS guidance of $4.90 at the midpoint and highlighted the impact of new product launches and expanding recurring service revenues, though Patient Care Solutions faced operational fulfillment headwinds and is undergoing a strategic review that could include divestiture. The company is advancing its innovation pipeline with upcoming launches like Photonova Spectra photon-counting CT and the ramp-up of Flyrcado, which targets $500 million in annual revenue by 2028.
GE HealthCare Technologies Inc.Beat Q2 revenue and EPS estimates, raised guidance midpoint, and record backlog.